phase III POSEIDON trial

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

phase III POSEIDON trial

Oct 16, 2024, 12:05 | Insight

Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer

Study finds patients with advanced non-small cell lung cancer and STK11 and/or KEAP1 mutations had…

Oct 11, 2024, 19:32 | Insight

Hung Trinh: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Hung Trinh shared a post on LinkedIn: “CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.…

All: 2 Posts: 1 - 100

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

'

King Charles III Hospitalized Following Side Effects from Cancer Treatment

'

Keith T. Flaherty has been elected as the AACR President-Elect for 2025-2026

'

MARIPOSA trial results presented at ELCC25 - BREAKING from Paris

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023